Changing strategies for target therapy in gastric cancer

Suk Young Lee, Sang Cheul Oh

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

In spite of a worldwide decrease in the incidence of gastric cancer, this malignancy still remains one of the leading causes of cancer mortality. Great efforts have been made to improve treatment outcomes in patients with metastatic gastric cancer, and the introduction of trastuzumab has greatly improved the overall survival. The trastuzumab treatment took its first step in opening the era of molecular targeted therapy, however several issues still need to be resolved to increase the efficacy of targeted therapy. Firstly, many patients with metastatic gastric cancer who receive trastuzumab in combination with chemotherapeutic agents develop resistance to the targeted therapy. Secondly, many clinical trials testing novel molecular targeted agents with demonstrated efficacy in other malignancies have failed to show benefit in patients with metastatic gastric cancer, suggesting the importance of the selection of appropriate indications according to molecular characteristics in application of targeted agents. Herein, we review the molecular targeted agents currently approved and in use, and clinical trials in patients with metastatic gastric cancer, and demonstrate the limitations and future direction in treatment of advanced gastric cancer.

Original languageEnglish
Pages (from-to)1179-1189
Number of pages11
JournalWorld Journal of Gastroenterology
Volume22
Issue number3
DOIs
Publication statusPublished - 2016 Jan 21

Fingerprint

Stomach Neoplasms
Therapeutics
Clinical Trials
Molecular Targeted Therapy
Neoplasms
Survival
Mortality
Incidence
Trastuzumab

Keywords

  • Advanced gastric cancer
  • Chemotherapy
  • Signal pathway
  • Strategy
  • Target therapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Changing strategies for target therapy in gastric cancer. / Lee, Suk Young; Oh, Sang Cheul.

In: World Journal of Gastroenterology, Vol. 22, No. 3, 21.01.2016, p. 1179-1189.

Research output: Contribution to journalArticle

@article{68c47c11f0a440e9817d6162d987d452,
title = "Changing strategies for target therapy in gastric cancer",
abstract = "In spite of a worldwide decrease in the incidence of gastric cancer, this malignancy still remains one of the leading causes of cancer mortality. Great efforts have been made to improve treatment outcomes in patients with metastatic gastric cancer, and the introduction of trastuzumab has greatly improved the overall survival. The trastuzumab treatment took its first step in opening the era of molecular targeted therapy, however several issues still need to be resolved to increase the efficacy of targeted therapy. Firstly, many patients with metastatic gastric cancer who receive trastuzumab in combination with chemotherapeutic agents develop resistance to the targeted therapy. Secondly, many clinical trials testing novel molecular targeted agents with demonstrated efficacy in other malignancies have failed to show benefit in patients with metastatic gastric cancer, suggesting the importance of the selection of appropriate indications according to molecular characteristics in application of targeted agents. Herein, we review the molecular targeted agents currently approved and in use, and clinical trials in patients with metastatic gastric cancer, and demonstrate the limitations and future direction in treatment of advanced gastric cancer.",
keywords = "Advanced gastric cancer, Chemotherapy, Signal pathway, Strategy, Target therapy",
author = "Lee, {Suk Young} and Oh, {Sang Cheul}",
year = "2016",
month = "1",
day = "21",
doi = "10.3748/wjg.v22.i3.1179",
language = "English",
volume = "22",
pages = "1179--1189",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "3",

}

TY - JOUR

T1 - Changing strategies for target therapy in gastric cancer

AU - Lee, Suk Young

AU - Oh, Sang Cheul

PY - 2016/1/21

Y1 - 2016/1/21

N2 - In spite of a worldwide decrease in the incidence of gastric cancer, this malignancy still remains one of the leading causes of cancer mortality. Great efforts have been made to improve treatment outcomes in patients with metastatic gastric cancer, and the introduction of trastuzumab has greatly improved the overall survival. The trastuzumab treatment took its first step in opening the era of molecular targeted therapy, however several issues still need to be resolved to increase the efficacy of targeted therapy. Firstly, many patients with metastatic gastric cancer who receive trastuzumab in combination with chemotherapeutic agents develop resistance to the targeted therapy. Secondly, many clinical trials testing novel molecular targeted agents with demonstrated efficacy in other malignancies have failed to show benefit in patients with metastatic gastric cancer, suggesting the importance of the selection of appropriate indications according to molecular characteristics in application of targeted agents. Herein, we review the molecular targeted agents currently approved and in use, and clinical trials in patients with metastatic gastric cancer, and demonstrate the limitations and future direction in treatment of advanced gastric cancer.

AB - In spite of a worldwide decrease in the incidence of gastric cancer, this malignancy still remains one of the leading causes of cancer mortality. Great efforts have been made to improve treatment outcomes in patients with metastatic gastric cancer, and the introduction of trastuzumab has greatly improved the overall survival. The trastuzumab treatment took its first step in opening the era of molecular targeted therapy, however several issues still need to be resolved to increase the efficacy of targeted therapy. Firstly, many patients with metastatic gastric cancer who receive trastuzumab in combination with chemotherapeutic agents develop resistance to the targeted therapy. Secondly, many clinical trials testing novel molecular targeted agents with demonstrated efficacy in other malignancies have failed to show benefit in patients with metastatic gastric cancer, suggesting the importance of the selection of appropriate indications according to molecular characteristics in application of targeted agents. Herein, we review the molecular targeted agents currently approved and in use, and clinical trials in patients with metastatic gastric cancer, and demonstrate the limitations and future direction in treatment of advanced gastric cancer.

KW - Advanced gastric cancer

KW - Chemotherapy

KW - Signal pathway

KW - Strategy

KW - Target therapy

UR - http://www.scopus.com/inward/record.url?scp=84961352156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961352156&partnerID=8YFLogxK

U2 - 10.3748/wjg.v22.i3.1179

DO - 10.3748/wjg.v22.i3.1179

M3 - Article

C2 - 26811656

AN - SCOPUS:84961352156

VL - 22

SP - 1179

EP - 1189

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 3

ER -